These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6547940)

  • 1. Nitroaryl compounds as potential fluorescent probes for hypoxia. II. Identification and properties of reductive metabolites.
    Stratford MR; Clarke ED; Hodgkiss RJ; Middleton RW; Wardman P
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1353-6. PubMed ID: 6547940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescent markers of hypoxic cells: a comparison of two compounds on three cell lines.
    Begg AC; Hodgkiss RJ; McNally NJ; Middleton RW; Stratford MR; Terry NH
    Br J Radiol; 1985 Jul; 58(691):645-54. PubMed ID: 3839428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroaryl compounds as potential fluorescent probes for hypoxia. I. Chemical criteria and constraints.
    Wardman P; Clarke ED; Hodgkiss RJ; Middleton RW; Parrick J; Stratford MR
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1347-51. PubMed ID: 6547939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroakridin 3582: a fluorescent nitroacridine stain for identifying hypoxic cells.
    Begg AC; Engelhardt EL; Hodgkiss RJ; McNally NJ; Terry NH; Wardman P
    Br J Radiol; 1983 Dec; 56(672):970-3. PubMed ID: 6197129
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluorescent markers for hypoxic cells. A study of novel heterocyclic compounds that undergo bio-reductive binding.
    Hodgkiss RJ; Begg AC; Middleton RW; Parrick J; Stratford MR; Wardman P; Wilson GD
    Biochem Pharmacol; 1991 Feb; 41(4):533-41. PubMed ID: 1705123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgehead-nitrogen, bicyclic systems.
    Hodgkiss RJ; Middleton RW; Parrick J; Rami HK; Wardman P; Wilson GD
    J Med Chem; 1992 May; 35(10):1920-6. PubMed ID: 1588568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel nitroheterocyclic hypoxic markers for solid tumor: synthesis and biological evaluation.
    Zhu W; Dai M; Xu Y; Qian X
    Bioorg Med Chem; 2008 Mar; 16(6):3255-60. PubMed ID: 18160298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measurement of oxygen concentration in tumor cells by fluorescent probe (nitrocompound)].
    Katoh T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Jun; 50(6):661-8. PubMed ID: 2235317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive metabolism and hypoxia-selective toxicity of nitracrine.
    Wilson WR; Denny WA; Stewart GM; Fenn A; Probert JC
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1235-8. PubMed ID: 3744944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-selective, enzymatic conversion of 6-nitroquinoline into a fluorescent helicene: pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide.
    Rajapakse A; Gates KS
    J Org Chem; 2012 Apr; 77(7):3531-7. PubMed ID: 22417220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between metabolic deactivation of ICR compounds and their differential mutagenicity in bacteria and cultured mammalian cells.
    De Flora S; Basso C; Camoirano A; Astengo M; Badolati GS
    Mutat Res; 1986 Jul; 174(3):227-32. PubMed ID: 2425256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aliphatic N-oxide of naphthalimides as fluorescent markers for hypoxic cells in solid tumor.
    Yin H; Zhu W; Xu Y; Dai M; Qian X; Li Y; Liu J
    Eur J Med Chem; 2011 Jul; 46(7):3030-7. PubMed ID: 21550698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescent markers for hypoxic cells: a study of nitroaromatic compounds, with fluorescent heterocyclic side chains, that undergo bioreductive binding.
    Hodgkiss RJ; Jones GW; Long A; Middleton RW; Parrick J; Stratford MR; Wardman P; Wilson GD
    J Med Chem; 1991 Jul; 34(7):2268-74. PubMed ID: 2066999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective deactivation of ICR mutagens as related to their distinctive pulmonary carcinogenicity.
    De Flora S; Morelli A; Zanacchi P; Bennicelli C; De Flora A
    Carcinogenesis; 1982; 3(2):187-94. PubMed ID: 6175436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and molecular analyses of ethyl methanesulfonate- and ICR 191-induced mutation in AS52 cells.
    Stankowski LF; Tindall KR; Hsie AW
    Mutat Res; 1986 Apr; 160(2):133-47. PubMed ID: 3512985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome aberrations induced by 9-aminoacridine derivatives.
    Michalska J
    Mutat Res; 1986 Jun; 170(3):119-23. PubMed ID: 3713722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe.
    Olive PL; Vikse C; Trotter MJ
    Int J Radiat Oncol Biol Phys; 1992; 22(3):397-402. PubMed ID: 1735668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of novel 8-oxo-8H-cyclopenta[a]acenaphthylene-7-carbonitriles as long-wavelength fluorescent markers for hypoxic cells in solid tumor.
    Liu Y; Xu Y; Qian X; Xiao Y; Liu J; Shen L; Li J; Zhang Y
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1562-6. PubMed ID: 16403630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia.
    Rasey JS; Koh WJ; Grierson JR; Grunbaum Z; Krohn KA
    Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):985-91. PubMed ID: 2808061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.